WilmerHale Advises PTC Therapeutics on Public Offering

WilmerHale Advises PTC Therapeutics on Public Offering

Client News

Related Solutions

Comprehensive counseling for healthcare providers, insurers and the companies that supply them with products and services.
Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.

On January 23, 2019, PTC Therapeutics, Inc. (NASDAQ: PTCT), a science-led, global biopharmaceutical company focused on the discovery, development and commercialization of clinically-differentiated medicines that provide benefits to patients with rare disorders, announced the pricing of a public offering of 6,720,000 shares of its common stock at a public offering price of $30.20, before underwriting discounts. In addition, PTC has granted the underwriter an option for a period of 30 days to purchase up to an additional 1,008,000 shares of common stock at the public offering price, less the underwriting discount. The closing of the offering took place on January 25, 2019.

WilmerHale represented PTC, with Brian Johnson leading the legal advisory team.

Read more about the firm's involvement.


Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.

I Accept Cancel